Literature DB >> 7747265

FDA classification of drugs for teratogenic risk. Teratology Society Public Affairs Committee.

.   

Abstract

The Teratology Society believes that the current FDA Use-in-Pregnancy Ratings should be abandoned. The Society recommends that drug labeling should include narrative statements that summarize and interpret available data regarding hazards of developmental toxicity and provide estimates of potential teratogenic risk.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7747265     DOI： 10.1002/tera.1420490603

Source DB:  PubMed          Journal:  Teratology        ISSN： 0040-3709


  16 in total

1.  Non-pharmacological interventions for sleep quality and insomnia during pregnancy: A systematic review.

Authors:  Dana Hollenbach; Riley Broker; Stacia Herlehy; Kent Stuber
Journal:  J Can Chiropr Assoc       Date:  2013-09

2.  Classification of drugs for teratogenic risk.

Authors:  G Alván; B R Danielsson; I Kihlström; P Lundborg; B Prame; E Ridley; R Sannerstedt
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 3.  Management of pregnant patient in dentistry.

Authors:  Sophia Kurien; Vivekanand S Kattimani; Roopa Rani Sriram; Sanjay Krishna Sriram; Prabhakara Rao V K; Anitha Bhupathi; Rupa Rani Bodduru; Namrata N Patil
Journal:  J Int Oral Health       Date:  2013-02-26

Review 4.  Treating hypertension in women of child-bearing age and during pregnancy.

Authors:  L A Magee
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 5.  Treating allergic rhinitis in pregnancy. Safety considerations.

Authors:  P Mazzotta; R Loebstein; G Koren
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

6.  Risk classification systems for drug use during pregnancy: are they a reliable source of information?

Authors:  A Addis; S Sharabi; M Bonati
Journal:  Drug Saf       Date:  2000-09       Impact factor: 5.606

Review 7.  Drugs during pregnancy: an issue of risk classification and information to prescribers.

Authors:  R Sannerstedt; P Lundborg; B R Danielsson; I Kihlström; G Alván; B Prame; E Ridley
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

8.  Dental considerations in pregnancy-a critical review on the oral care.

Authors:  Hemalatha Vt; Manigandan T; Sarumathi T; Aarthi Nisha V; Amudhan A
Journal:  J Clin Diagn Res       Date:  2013-03-21

9.  Developing a systematic approach to safer medication use during pregnancy: summary of a Centers for Disease Control and Prevention--convened meeting.

Authors:  Cheryl S Broussard; Meghan T Frey; Sonia Hernandez-Diaz; Michael F Greene; Christina D Chambers; Leyla Sahin; Beth A Collins Sharp; Margaret A Honein
Journal:  Am J Obstet Gynecol       Date:  2014-05-29       Impact factor: 8.661

Review 10.  Therapeutic management of epithelial ovarian cancer during pregnancy.

Authors:  L Minig; L Otaño; I Diaz-Padilla; R Alvarez Gallego; M G Patrono; J Valero de Bernabé
Journal:  Clin Transl Oncol       Date:  2012-11-21       Impact factor: 3.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.